Drug Conjugate for Early Cancer Diagnosis and Reduced Chemotherapy Side Effects

Back to all technologies
Download as PDF
2017-LOW-67871
Cancer is a deadly disease that affects many people around the world. However, current chemotherapy is associated with a litany of unwanted side effects. In addition, existing treatment does not diagnose malignant stages fast enough for effective treatment. There is need of a method for reducing both the time of diagnosis and the side effects associated with traditional chemotherapy.

Researchers at Purdue University have developed a small molecule drug conjugate (SMDC) for cancer treatment. The drug would provide an option for patients who want to achieve early diagnosis and better treat tumors by avoiding the many side effects of traditional chemotherapy like nausea and hair loss. This drug would target chemotherapy drugs and radioimaging agents to help oncologists treat cancer patients in early malignant stages.

Advantages:
-Reduced side effects
-Early diagnosis

Potential Applications:
-Chemotherapy drugs
-Radioimaging agents
Dec 30, 2020
EP-Patent
Hong Kong
(None)
(None)

Dec 2, 2020
EP-Patent
Hong Kong
(None)
(None)

Feb 21, 2020
NATL-Patent
Japan
(None)
(None)

Feb 20, 2020
NATL-Patent
United States
(None)
(None)

Aug 21, 2018
PCT-Patent
WO
(None)
(None)

Aug 21, 2018
NATL-Patent
Europe
(None)
(None)

Aug 21, 2018
NATL-Patent
China
(None)
(None)

Aug 22, 2017
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org